Uso de bifosfonatos pdf

Por ejemplo, tomar medicamentos inyectables en vez de una pastilla puede hacer que la acidez estomacal desaparezca. Otros medicamentos para la osteoporosis son Denosumab, un medicamento que detiene el deterioro de los huesos y reduce el riesgo de fracturas, lo que incluye las fracturas de cadera.

Raloxifene, un medicamento que detiene el deterioro de los huesos y reduce el riesgo de algunos tipos de fracturas. En general, si usted toma este tipo de medicamento, la probabilidad de prevenir fracturas es alta y el riesgo de problemas serios es bajo. Oxford University Press is a department of the University of Oxford.

It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Bifosfonatos para la osteoporosis: Beneficios y riesgos.

Oxford Academic. Google Scholar. James V. Hennessey, MD. Leonard Wartofsky, MD. Select Format Select format. Permissions Icon Permissions. Freedholm, et al. Esophagitis associated with the use of alendronate. Vestergaard, K. Schwartz, E. Pinholt, L. Rejnmark, L. Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int. Bobba, K. Beattie, B. Parkinson, D.

Kumbhare, J. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf. Cadarette, J. Katz, M. Brookhart, T. Sturmer, M. Stedman, R. Levin, et al. Comparative gastrointestinal safety of weekly oral bisphosphonates. Osteoporos Int. Reports of esophageal cancer with oral bisphosphonate use. Eiken, R. More on reports of esophageal cancer with oral bisphosphonate use.

Solomon, A. Patrick, M. De Vries, A. Cooper, S. Cockle, T. Van Staa, C. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.

French, C. Postmarketing surveillance of uveitis and scleritis with bisphosphonates among a national veteran cohort. Aurich-Barrera, L. Wilton, S. Harris, S. Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England. Drug Safety. Malik, S. Campbell, N. Bilateral acute anterior uveitis after alendronate. Br J Ophthalmol. Fraunfelder, F.

Fraunfelder, B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol. El Saghir, Z. Otrock, J.

Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer. BMC Cancer. Leung, B. Ashar, R. Bisphosphonate-associated scleritis: a case report and review. South Med J. Benderson, Karakunnel, S. Kathuria, A. Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma. Kilickap, Y. Ozdamar, M. Altundag, O. A case report: zoledronic acid induced uveitis. Med Oncol. Nodular scleritis following alendronate therapy.

Ocul Immunol Inflamm. Colucci, G. Modorati, E. Miserocchi, F. Di Matteo, P. Anterior uveitis complicating zoledronic acid infusion. Carbonell Abello. Ocular toxicity, bisphosphonate and Paget disease. Med Clin Barc. Tan, J. Sims, S. Bilateral uveitis secondary to bisphosphonate therapy. Procianoy, E. Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis.

Dasanu, D. Acute retinal pigment epithelial detachment secondary to pamidronate administration. J Oncol Pharm Pract. Raja, P. Sandanshiv, M. Risedronate induced transient ocular myasthenia. J Postgrad Med. Seth, D. Anderson, D. Albiani, J. Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer.

Can J Ophthalmol. Miura, N. Mizuno, R. Massive proteinuria and acute renal failure after oral bisphosphonate alendronate administration in a patient with segmental glomerulosclerosis. Clin Exp Nephrol. Rosen, D. Kaminski, A. Howell, A. Belch, J.

Mackey, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Chang, L. Green, J. Renal failure with the use of zoledronic acid. The issue of renal safety of zoledronic acid from a nephrologist's point of view. Perazella, G. Kidney Int. The risk of cumulative renal effects of intravenous bisphosphonates.

Support Cancer Ther. Jassal, D. Von Muhlen, E. J Bone Min Res. Chennuru, J. Koduri, M. Risk factors for symtomatic hypocalcemia complicating treatment with zoledronic acid. Intern Med J. Zuradelli, G. Masci, G. Biancofiore, G. Gullo, M. Scorsetti, P. Navarria, et al. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.

Schussheim, T. Jacobs, S. Ann Intern Med. Liamis, H. Milionis, M. J Bone Miner Metab. Maalouf, H. Heller, C. Odvina, P. Kim, K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. Adami, A. Bhalla, R. Dorizzi, F. Montesanti, S. Rosini, G. Salvagno, et al. The acute-phase response after bisphosphonate administration.

Olson, C. Van Poznak. Significance and impact of bisphosphonate-induced acute phase responses. Casseti, A. The plasticity of gammadelta T Cells: innate immunity, antigen presentation and new immunotherapy. Cell Mol Immunol. Tanaka, C. Morita, Y. Tanaka, E. Nieves, M. Brenner, B.

Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Gober, M. Kistowska, L. Angman, P. Jeno, L. Mori, G. De Libero, Human T. J Exp Med. Galluzzo, D. Santini, B. Vincenzi, N.

Caccamo, F. Meraviglia, A. Salerno, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets, 7 , pp. Thompson, M. Statins prevent bisphosphonate-induced gamma-delta-T-cell proliferation and activation in vitro.

J Bone Miner Res. Hewitt, A. Lissina, A. Green, E. Slay, D. Price, A. Clin Exp Immunol. Srivastava, C. Haney, U. Atorvastatin may have no effect on acute phase reaction in children following intravenous bisphosphonate infusion. Bertoldo, S. Pancheri, S.

Zenari, S. Boldini, B. Giovanazzi, M. Zanatta, et al. Serum 25 OH D levels modulate the Acute Phase Response associated to the first nitrogen containing bisphosphonate infusion. Black, P. Delmas, R. Eastell, I. Reid, S. Boonen, J. Cauley, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. Cummings, A. Schwartz, D. N End J Med.

Christensen, F. Mehnert, L. Pedersen, R. Chapurlat, S. Cummings, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BE Medline. Heckbert, G.

Li, S. Cummings, N. Smith, B. Use of alendronate and risk of incident atrial fibrillation in women. Arch Int Med. Lyles, C. Magaziner, J. Adachi, C. Pieper, C. Mautalen, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. Wysowski, J. Alendronate and risedronate: reports of severe bone, joint, and muscle pain.

Arch Intern Med. Bock, H. Boerst, F. Thomasius, C. Degner, M. Stephan-Oelkers, S. Valentine, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.

J Musculoskelet Neuronal Interact. Information for healthcare professionals: bisphosphonates. Published January 7, Caplan, C. Pittman, A. Zeringue, J. Scherrer, K. Wehmeier, F. Cunningham, et al. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy.

Mayo Clin Proc. Yemisci, S. Yalbuzdag, M. J Clin Rheumatol. Gwynne Jones, R. Savage, J. J Rheumatol. Frederiksen, P. Junker, K. Persistent polyarticular synovitis after treatment with alendronate. Ugeskr Laeger. Odvina, J. Zerwekh, E. Rao, N. Maalouf, F. Gottschalk, C. Severely suppressed bone turnover: a potential complication of alendronate therapy.

J Clin Endocrinol Metab. Renal bone disease: a new conceptual framework for interpretation of bone histomorphometry.

Curr Opin Nephrol Hypertens. Visekruna, D. Wilson, F. Severely suppressed bone turnover and atypical skeletal fragility. Gosh, K. Yang, J. Koh, M. Wong, S. Chua, D. Chua, et al.